Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Susan Sheng, Matthew Thayer, Rafael Bejar, Stephen Howell, William Rice

Cancer Res (2020) 80 (16_Supplement): CT239.

DOI: https://doi.org/10.1158/1538-7445.AM2020-CT239

Published: 15 August 2020

View article

Journal Articles

Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas

Nasrin Rastgoo, Matthew Thayer, Khalid Benbatoul, Stephen Howell, William Rice, Hongying Zhang

Cancer Res (2020) 80 (16_Supplement): 4225.

DOI: https://doi.org/10.1158/1538-7445.AM2020-4225

Published: 15 August 2020

View article

Journal Articles

Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells

Andrea Local, Cheng-Yu Tsai, Hongying Zhang, Susan Sheng, Khalid Benbatoul, Stephen B. Howell, William G. Rice

Cancer Res (2019) 79 (13_Supplement): 2096.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2096

Published: 01 July 2019

View article

Journal Articles

Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Hongying Zhang, Andrea Local, Khalid Benbatoul, Peter Folger, Susan Sheng, Cheng-Yu Tsai, Stephen B. Howell, William G. Rice

Cancer Res (2018) 78 (13_Supplement): 794.

DOI: https://doi.org/10.1158/1538-7445.AM2018-794

Published: 01 July 2018

View article

Journal Articles

Abstract 5703: Efficient targeted delivery of protein toxins using self-manufacturing nanoparticles (minicells) derived from bacteria

Michael J. Newman, Khalid Benbatoul, Bryan Hancock, Veronica Hernandez, Shingo Tsuji, Jacques Weissman, Matthew J. Giacalone

Cancer Res (2012) 72 (8_Supplement): 5703.

DOI: https://doi.org/10.1158/1538-7445.AM2012-5703

Published: 15 April 2012

View article

NARROW

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas

Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells

Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Abstract 5703: Efficient targeted delivery of protein toxins using self-manufacturing nanoparticles (minicells) derived from bacteria

Email alerts

AACR Journals

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas

Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells

Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Abstract 5703: Efficient targeted delivery of protein toxins using self-manufacturing nanoparticles (minicells) derived from bacteria

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only